Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Kezar Life Sciences has raised $12.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2022.
Kezar Life Sciences's investors include Qiming Venture Partners, Cormorant Asset Management, Oxford Finance LLC, Omega Funds, EcoR1 Capital.
Kezar Life Sciences is headquartered in South San Francisco, United States.
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Kezar Life Sciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kezar Life Sciences — Funding & Investors." VCBacked, October 3, 2022, https://www.vcbacked.co/company/kezar-life-sciences. Accessed July 20, 2026.
VCBacked. (2022). Kezar Life Sciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/kezar-life-sciences
{{cite web |title=Kezar Life Sciences — Funding & Investors |url=https://www.vcbacked.co/company/kezar-life-sciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated